TNFRSF12A and neoplasm: Outcomes showed that patients belonging to the Luminal group (ER+) had a statistically significant higher risk to develop BrM if the tumor expressed FN14 compared with those with FN14 negative tumors (OR: 36.70; 95% CI: 3.65–368.25; p = 0.002).